FDA approves trastuzumab deruxtecan (T-DXd) plus pertuzumab for first-line treatment of HER2-positive metastatic breast cancer. The approval is supported by randomized phase 3 data demonstrating a significant improvement in progression-free…
Interactive Cancer Care Network (ICCN) strives to provide Community Oncologists with medical education regarding the most up to date drug approvals and treatment landscape changes. Providing insights from national key opinion leaders allows for the opportunity to ask questions relevant to your clinical practice. At this time we offer virtual programs tailoring to the busy schedules of medical providers. We look forward to having you join the ICCN community.